Incyte (INCY) announced the first clinical data evaluating its TGFbetaR2PD-1 bispecific antibody for patients with microsatellite stable, MSS, ...

Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ...

Nurix Therapeutics (NRIX) announced the presentation of new clinical data from its first-in-human Phase 1a study of NX-1607, a first-in-class oral ...

Stop to reveal the personal and professional drive behind a groundbreaking special issue of Prehospital Emergency Care ...

Revolutionary AI assistant RISA eliminates the pain of hunting for patient data across multiple systems, enabling clinicians to focus more on patient ...

Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...

(PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –All clinical ...

Moderna Inc. (NASDAQ: MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, ...

Survival models using EHR data predicted progression from NPDR or DME to PDR in type 2 diabetes patients. Key risk factors for progression included age, race, NPDR severity, and diabetic nephropathy.

TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in biomarker-unselected, heavily pre-treated PROC patients At data-cut-off on September ...